Tailwinds’ Take: this stock represents the definition of “tailwinds”. They have a very large secular move happening underneath them and they are the only option when it comes to shipping these therapeutics, so are a direct beneficiary of all growth. Not a cheap stock, but can will grow into the valuation.
IRVINE, Calif., May 3, 2018 /PRNewswire/ — Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) (“Cryoport” or the “Company”), the global leader in temperature-controlled logistics dedicated to the life sciences industry, today announced financial results for the three-month period ended March 31, 2018.
“Our First Quarter revenue increased 48% year-over-year, or 21% sequentially, to $4 million,” Jerrell Shelton, Chief Executive Officer of Cryoport, commented. “This was another strong quarter for Cryoport as we continue to ramp reported revenue from our commercial agreements to provide logistics support for Gilead’s Yescarta™ and Novartis’ Kymriah™, the first two FDA-approved CAR-T therapies. We believe the rollout of these therapies will accelerate based on our clients’ schedules; thus, driving significant revenue growth for the Company for the remainder of 2018 and beyond. Moreover, the FDA has just approved Novartis’ Kymriah™ for its second indication, the treatment of adult patients with relapsed or refractory large B-cell lymphoma, which will drive further expansion of our logistics support to Novartis.
“We also continued to grow the foundation for medium and long-term growth during the first quarter as we increased the number of clinical trials we support by 22, bringing the total number of clinical trials we support to a record 236, up from 214 at the end of the fourth quarter of 2017, and 139 at the end of the first quarter of 2017. Significantly, 31 of these clinical trials currently supported by Cryoport are now in Phase III. Furthermore, we anticipate supporting five or six additional BLA or EMA filings in 2018, based on internal information and a forecast from the Alliance for Regenerative Medicine, in addition to Kymriah’s second indication FDA approval.
“This growth in our clinical trial support programs represents embedded revenue growth, and together with the anticipated rollout of Gilead’s and Novartis’ commercial therapies, should fuel significant top line revenue growth for the remainder of 2018 and beyond. As a result of these developments and our infrastructure buildout, Cryoport, by all measures, is in the strongest position it has ever been. Most assuredly, we will continue to work diligently to maintain our market position as the new wave of regenerative therapies roll out and provide patients with potentially life-saving treatment alternatives. Our role in the personalized medicine market presents Cryoport with increasing opportunities to serve this revolution in medicine and build shareholder value for many years.
“In addition to the tremendous growth opportunities in the Biopharma market, we also continue to believe that both the Reproductive Medicine and Animal Health markets have considerable upside for growth,” concluded Mr. Shelton.
- Biopharma revenue increased by 62% in the three months ended March 31, 2018 compared to the same period in 2017.
- 22 new biopharma trials were added in the three-months ended March 31, 2018.
- Cryoport is supporting a net total of 236 clinical trials compared with 139 as of March 31, 2017. The number of trials in Phase III grew from 17 to 31 during the quarter.
- Provided logistics support to Novartis as it continues its commercial launch of Kymriah™.
- Provided logistics support to Gilead’s Kite as it continues its commercial launch of Yescarta™.
- Announced a new collaboration with McKesson Specialty Health, a division of McKesson Corporation, designed to embed our logistics solutions into the ecosystems that are emerging to support delivery of cell and gene therapies to patients at points of care.
- Continued construction of two new state of the art Cryoport Logistics Centres, located in New Jersey and the Netherlands, both with scheduled openings during the June/July timeframe of 2018.
- Revenue from the Animal Health market was down 12% for the three months ended March 31, 2018 compared to the same period in 2017, primarily as a result of a temporary pause of a trial conducted by one of our clients.
- Reproductive Medicine revenue increased by 20% for the three months ended March 31, 2018 compared to the same period in 2017, driven by continuing domestic demand.
- Revenue increased 48% to $4.0 million for the three-month period ended March 31, 2018 compared to the same period in 2017. This growth was driven by an overall increase in the number of clients utilizing the Company’s solutions, complemented by growth and frequency of shipments from current clients.
- Gross margin for the three-months ended March 31, 2018 was 54%, compared to 46% for the same period in 2017, representing an increase by 8 percentage points. Gross margin improvements were driven by increased business volume and the positive impact of economies of scale.
- As a result of investments in the build out of infrastructure, which includes adding new competencies and services, operating costs and expenses increased by 32% or $1.0 million for three months ended March 31, 2018.
- Adjusted EBITDA for the three-month period ended March 31, 2018 continued to improve to $(0.5) million, compared with $(0.9) million for the same three-month period in the prior year.
- The Company has no debt and reported $19.0 million in cash and cash equivalents as of March 31, 2018, compared to $15.0 million as of December 31, 2017. The increase in cash and cash equivalents includes net proceeds of $4.6 million received from a warrant tender offer during the three-month period ended March 31, 2018.
Further information on Cryoport’s financial results is included on the attached condensed consolidated balance sheets and statements of operations, and additional explanations of Cryoport’s financial performance is provided in Cryoport’s annual report on Form 10-Q for the three-month period ended March 31, 2018, which will be filed with the Securities and Exchange Commission (“SEC”) on May 3, 2018. The full report will be available on the SEC Filings section of the Investor Relations section of the Company’s website at www.cryoport.com.
Earnings Conference Call Information
Thursday, May 3, 2018
4:30 p.m. ET
+1 (877) 407-9716 (U.S.) or +1 (201) 493-6779 (International)
Request “Cryoport Call”
Investor Relations section at www.cryoport.com or at this link. Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.
An archive of the webcast will be available approximately three hours after completion of the live event and will be accessible on the Investor Relations section of the Company’s website at www.cryoport.com for a limited time. To access the replay of the webcast, please follow this link. A dial-in replay of the call will also be available to those interested until May 10, 2018. To access the replay, dial 1 (844) 512-2921 (United States) or 1 (412) 317-6671 (International) and enter replay pin number: 13678990.
About Cryoport, Inc.
Cryoport is the life sciences industry’s most trusted global provider of temperature-controlled logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport’s solutions are used by points-of-care, CRO’s, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport’s proprietary Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.
Cryoport is dedicated to:
- simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting;
- delivering the most advanced temperature controlled logistics solutions for the life sciences industry; and
- providing vital information that provides peace of mind throughout the life of each logistics process.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company’s cash flow, market acceptance risks, and technical development risks. The Company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the Company’s SEC reports including, but not limited to, the Company’s 10-K for the year ended December 31, 2017 filed with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.